Deals
Roche Willing to Consider Added ‘Value’ in Illumina Bid
This article is for subscribers only.
Roche Holding AG said it is willing to study “additional value” in its bid for Illumina Inc. after a proxy-advisory firm recommended that the target company’s shareholders reject the hostile offer.
Roche’s concession was tied to “the opportunity to enter discussions and perform due diligence” in preparation for a possible deal, the Basel, Switzerland-based drugmaker said in an e-mailed statement yesterday.